CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 39 enrolled
Drug / intervention
Escitalopram +1 moredrug
Likely dose
Escitalopram 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00824044
NCT00824044Phase 4Completed

QEEG Predictors of Response for Psychotherapy Compared to Pharmacotherapy in Depression

Massachusetts General Hospital·interventional·Posted Jan 16, 2009·Updated Jan 5, 2018

In Brief

A Phase 4 clinical trial evaluating Cognitive Behavioral Therapy (CBT) and Escitalopram for Major Depressive Disorder. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The purpose of this research study is to find out if a test can predict whether someone with depression will get better with treatment. We also want to find out whether there are changes in the brains of depressed patients having different types of treatment (drug therapy vs. talk therapy). We hope that a test called QEEG (Quantitative Electroencephalogram) can tell us if a treatment is going to work, even before the person starts to feel better. Hypothesis 1: Response to treatment will correlate with changes in QEEG metrics. Hypothesis 2: QEEG parameters, different from those that predict response to pharmacotherapy, will be associated with response to CBT.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 16, 2009
Enrollment StartJul 1, 2008
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 17.5 years ago

Interventions

Cognitive Behavioral Therapy (CBT)behavioral

The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.

Escitalopramdrug

The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.